Evaxion Biotech A/S (NASDAQ:EVAX) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $14.00 target price on the stock.

Evaxion Biotech A/S Stock Performance

NASDAQ EVAX opened at $3.12 on Thursday. The company has a market cap of $17.41 million, a P/E ratio of -0.72 and a beta of -0.27. Evaxion Biotech A/S has a 1-year low of $2.26 and a 1-year high of $13.61. The company has a debt-to-equity ratio of 7.99, a current ratio of 2.80 and a quick ratio of 2.80. The stock has a 50-day moving average of $3.00 and a two-hundred day moving average of $3.31.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.14). The company had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same period in the prior year, the business earned ($2.10) EPS. As a group, analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EVAX. LM Advisors LLC purchased a new position in shares of Evaxion Biotech A/S in the 4th quarter valued at about $231,000. Invst LLC purchased a new position in Evaxion Biotech A/S in the second quarter worth approximately $156,000. Finally, Armistice Capital LLC grew its holdings in Evaxion Biotech A/S by 6.8% during the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after acquiring an additional 25,000 shares in the last quarter. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.